MYD88 and hepatocellular carcinoma: Furthermore, immunohistochemical (IHC) staining was performed to reassess the biological effects of MyD88 in HCC patients undergoing immune checkpoint inhibitor (ICI) therapy.<h4>Results</h4>Our pan-cancer data analysis further highlights the significant impact of MYD88 on clinical outcomes in HCC.